Wed, May 14, 10:09 AM (30 days ago)
**Yubo International Biotech Limited (YBGJ) Q1 2025 Financial Summary** **Financial Health & Performance:** - **Revenue:** $0 for Q1 2025 (vs. $3,488 in Q1 2024). - **Gross Profit:** $0 for Q1 2025 (vs. $2,661 in Q1 2024). - **Operating Expenses:** $467,299 for Q1 2025 (vs. $412,082 in Q1 2024). - **Net Loss:** $467,318 for Q1 2025 (vs. $409,505 in Q1 2024). - **Cash Flow:** Net cash used in operating activities was $(392,045) for Q1 2025 (vs. $(330,602) in Q1 2024). **Profit Margins:** - **Operating Margin:** -100% for Q1 2025 (vs. -117.5% in Q1 2024). - **Net Margin:** -100% for Q1 2025 (vs. -117.6% in Q1 2024). **Cash Flow:** - **Operating Cash Flow:** $(392,045) for Q1 2025 (vs. $(330,602) in Q1 2024). - **Investing Cash Flow:** $(6,186) for Q1 2025 (vs. $(30,006) in Q1 2024). - **Financing Cash Flow:** $277,780 for Q1 2025 (vs. $308,188 in Q1 2024). **Earnings Changes:** - **Quarter-over-Quarter (QoQ) Change in Net Loss:** Increased by $57,813 (14.1% increase). **Quarterly Performance Discussion:** - **Revenue:** No sales were made in Q1 2025, attributed to market and economic conditions in China. - **Expenses:** Increase in employee compensation and occupancy expenses. - **Liquidity:** Cash on hand was $9,773 with negative working capital of $4,096,572. - **Going Concern:** Substantial doubt about the ability to continue as a going concern due to recurring operating losses. **Trends & Uncertainties:** - **Market Conditions:** Downturn in China's market and economic conditions. - **Regulatory Risks:** Uncertainties related to PRC laws and regulations, including cybersecurity and data privacy. - **Operational Risks:** Dependence on a limited number of customers and potential disruptions in operations. **Future Operations Impact:** - **Funding:** Reliance on financial support from major shareholders and potential third-party financing. - **Strategic Initiatives:** Focus on identifying new sources of financing and expanding operations. **Key Risks:** - **Regulatory:** Changes in PRC laws and regulations could impact operations and financial performance. - **Operational:** Dependence on a limited customer base and potential disruptions in supply chain. - **Financial:** Need for additional capital to sustain operations and expand. **Conclusion:** Yubo International Biotech Limited faced significant financial challenges in Q1 2025, with no revenue and increased operating expenses leading to a higher net loss. The company's ability to continue as a going concern is uncertain, and it relies on financial support from major shareholders. Regulatory and operational risks, along with the need for additional funding, pose significant challenges for future operations.